biosimilars

Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
Samsung Bioepis' First Cancer Biosimilar Approved by the FDA
BioSpace
FDA
Samsung Bioepis
Ontruzant
biosimilars
Genentech
Herceptin
Flag link:
FDA Approves 17th Biosimilar, Third for Herceptin
FDA Approves 17th Biosimilar, Third for Herceptin
RAPS.org
FDA
Merck
Samsung Bioepis
Ontruzant
biosimilars
Roche
Herceptin
Flag link:
Pfizer once again takes out the budget ax and lops off 150 R&D staffers and 5 preclinical biosimilar drugs
Pfizer once again takes out the budget ax and lops off 150 R&D staffers and 5 preclinical biosimilar drugs
Endpoints
Pfizer
R&D
biosimilars
layoffs
Flag link:
Are Scare Tactics Being Used to Avoid Biosimilar Competition?
Are Scare Tactics Being Used to Avoid Biosimilar Competition?
BioSpace
biosimilars
competition
drug marketing
Flag link:
FDA approves Celltrion's Herceptin biosimilar
FDA approves Celltrion's Herceptin biosimilar
BioCentury
FDA
Herceptin
biosimilars
Celltrion
HER2-positive metastatic breast cancer
Flag link:
FDA Rolls Out Expectations for Biosimilars, Soon-to-Be Biologics
FDA Rolls Out Expectations for Biosimilars, Soon-to-Be Biologics
RAPS.org
FDA
biosimilars
biologics
BPCIA
Flag link:
Biosimilar makers back Pfizer in call to end misleading brand marketing
Biosimilar makers back Pfizer in call to end misleading brand marketing
BioCentury
FDA
Pfizer
biosimilars
Flag link:
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
AbbVie inks Humira patent deal No. 7, delaying Pfizer's U.S. biosim launch until late 2023
Fierce Pharma
AbbVie
biosimilars
Pfizer
Humira
patents
Flag link:
Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Spotlight on drug pricing could be catalyst for change in US biosimilar landscape
Endpoints
drug pricing
biosimilars
Flag link:
FDA approves first biosimilar for NHL
FDA approves first biosimilar for NHL
BioCentury
Celltrion
Teva Pharmaceutical
non-Hodgkin's lymphoma
Truxima
biosimilars
rituximab
Flag link:
Boehringer dropping ex-U.S. biosimilars programs
Boehringer dropping ex-U.S. biosimilars programs
BioCentury
Boehringer Ingelheim
biosimilars
Flag link:
Momenta Moves On
Momenta Moves On
Motley Fool
Momenta
earnings
biosimilars
M281
M254
Flag link:
Novartis Calls for FDA Enforcement Against Biosimilar Misinformation
Novartis Calls for FDA Enforcement Against Biosimilar Misinformation
RAPS.org
Novartis
FDA
biosimilars
citizen petitions
Flag link:
Pfizer launches biosimilar version of Amgen's Epogen
Pfizer launches biosimilar version of Amgen's Epogen
Biopharma Dive
Pfizer
biosimilars
Amgen
Epogen
JNJ
Procrit
anemia
Flag link:
The dynamics of the biosimilars market
The dynamics of the biosimilars market
GoinPharma
biosimilars
Flag link:
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount
Reuters
Coherus Biosciences
Amgen
biosimilars
Neulasta
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:
AbbVie staves off 6th Humira biosimilar in US
AbbVie staves off 6th Humira biosimilar in US
Biopharma Dive
AbbVie
Humira
biosimilars
Momenta Pharmaceuticals
Flag link:
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million
BioSpace
Biogen
Samsung Bioepis
biosimilars
Flag link:
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Novartis
Sandoz
FDA
biosimilars
Roche
Rituxan
Flag link:

Pages